In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merck invests in Chinese oncology start-up BeiGene

Executive Summary

Merck & Co. Inc. and its ex-US division Merck Sharp & Dohme are continuing their commitment to grow the company in China through an investment in Beijing-based oncology start-up BeiGene Ltd. The amount of Merck’s contribution--which was a combination of debt and equity--was not disclosed, but a BeiGene executive termed it “substantial.”
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
    • Large Molecule
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity

Related Companies